Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Glycot Therapeutics LLC
Profile last edited on: 9/6/2023      CAGE: 7FQT6      UEI: Q9DESREWJJ39

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2015
First Award
2017
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4991 Wild Olive Court
Ellicott City, MD 21042
   (301) 405-3949
   info@glycot.com
   www.glycot.com
Location: Single
Congr. District: 03
County: Howard

Public Profile

Glycot Therapeutics is structured around applying the firm's innovative and proprietary chemoenzymatic platform technology for glycoengineering of glycoprotein therapeutics, including therapeutic antibodies, to improve their therapeutic efficacy.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
2
Conversion Rate
50.00%
Phase I Dollars
$893,204
Phase II Dollars
$2,897,861
Total Awarded
$3,791,065

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $321,239
Project Title: Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation
2022 2 NIH $1,788,600
Project Title: Development of Streamlined Chemoenzymatic Glycan Remodeling Systems for Antibodies and Other Important Glycoproteins
2020 2 NIH $1,478,107
Project Title: Chemoenzymatic glycan remodeling of IVIG for improved anti-inflammatory activity
2018 1 NIH $292,823
Project Title: Chemoenzymatic Synthesis of Stable Isotope-Labeled Glycopeptides as Internal Standards for Glycosylation Quantitation

Key People / Management

  Lai-Xi Wang -- Founder and President

  Qiang Yang -- Founding Partner and Research Director

Company News

There are no news available.